.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,173,038

« Back to Dashboard
Patent 7,173,038 protects CAPRELSA and is included in one NDA.

This patent has fifty-three patent family members in thirty-three countries.

Summary for Patent: 7,173,038

Title:Quinazoline derivatives as VEGF inhibitors
Abstract:The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R.sup.1 represents halogeno or C.sub.1-3alkyl; X.sup.1 represents --O--; R.sup.2 is selected from one of the following three groups: 1) C.sub.1-5alkylR.sup.3 (wherein R.sup.3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C.sub.1-4hydroxyalkyl and C.sub.1-4alkoxy; 2) C.sub.2-5alkenylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); 3) C.sub.2-5alkynylR.sup.3 (wherein R.sup.3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as a active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of number of disease states including cancer and rheumatoid arthritis.
Inventor(s): Thomas; Andrew Peter (Macclesfield Cheshire, GB), Stokes; Elaine Sophie Elizabeth (Macclesfield Cheshire, GB), Hennequin; Laurent Francois Andre (Reims Cedex, FR)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/129,336
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 161st percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-001Apr 6, 2011RXNo7,173,038► subscribeYY
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYes7,173,038► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,173,038

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99402759Nov 05, 1999
99402877Nov 19, 1999
PCT Information
PCT FiledNovember 01, 2000PCT Application Number:PCT/GB00/04181
PCT Publication Date:May 10, 2001PCT Publication Number: WO01/32651

Non-Orange Book Patents for Patent: 7,173,038

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,642,608Quinazoline derivatives as VEGF inhibitors► subscribe
9,040,548Quinazoline derivatives as VEGF inhibitors► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,173,038

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1676845► subscribe
Slovenia1244647► subscribe
Russian Federation2291868► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc